• 1
    Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 110: 50717.
  • 2
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Botel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 137188.
  • 3
    Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985; 69: 2378.
  • 4
    Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 165462.
  • 5
    Kim SY, Suzuki N, Laxmi YRS, Shibutani S. Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 2004; 36: 199218.
  • 6
    Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001; 22: 83949.
  • 7
    Han X, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992; 52: 13603.
  • 8
    White INH, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 1992; 13: 2197203.
  • 9
    Shibutani S, Suzuki N, Laxmi YRS, Schild LJ, Divi RL, Grollman AP, Poirier MC. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 2003; 63: 44026.
  • 10
    Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP, Pearl ML. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000; 21: 14617.
  • 11
    Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White IN. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003; 63: 84615.
  • 12
    Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M, Kawarabayashi T. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br J Cancer 2005; 92: 1098103.
  • 13
    Terashima I, Suzuki N, Shibutani S. Mutagenic potential of α-(N2-deoxyguanosinyl)tamoxifen lesions: the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 1999; 59: 20915.
  • 14
    Kim SY, Suzuki N, Laxmi YRS, Shibutani S. Inefficient repair of tamoxifen-DNA adducts in rats and mice. Drug Metab Dispos 2006; 34: 31117.
  • 15
    Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem 1990; 36: 1915.
  • 16
    O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998; 90: 15528.
  • 17
    Buzdar A, Hortobagyi GN. Tamoxifen and toremifene in breast cancer comparison of safety and efficacy. J Clin Oncol 1998; 16: 34853.
  • 18
    FDA. FDA approves new uses for Evista. Available at Accessed on September 14, 2007.
  • 19
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 12534.
  • 20
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 16417.
  • 21
    Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL, Dakhil S, Lockhart JB, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 274251.
  • 22
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK for the Raloxifene Use for the Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 12537.
  • 23
    Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002; 30: 694700.
  • 24
    Jeong EJ, Liu Y, Lin H, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 2005; 33: 78594.
  • 25
    Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000; 57: 166975; quiz 1676–8.
  • 26
    Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53: 453441.
  • 27
    Kim SY, Suzuki N, Laxmi YRS, Umemoto A, Matsuda T, Shibutani S. Antiestrogens and the formation of DNA damage in rats: a comparison. Chem Res Toxicol 2006; 19: 8528.
  • 28
    Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YRS, Kanno Y, Suzuki M, Apak TI, Sheng JJ, Duffel MW. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 2001; 61: 392531.
  • 29
    Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 1997; 76: 7004.
  • 30
    Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP. Comparative analysis of mechanistic differences among antiestrogens. Endocrinology 1999; 140: 582840.
  • 31
    Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, Moore LB, Oliver BB, Sauls HR, Triantafillou JA, Wolfe SG, Baer PG. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994; 37: 15502.
  • 32
    Gauthier S, Mailhot J, Labrie F. New stereoselective synthesis of Z-4-hydroxy-TAM and Z-4-OH-TOR via Mcmurry reaction. J Org Chem 1996; 61: 38903.
  • 33
    Kaltenbach R, Robinson S, Trainor G. Preparation of triphenylethylene derivatives as selective estrogen receptor modulators. PCT Int Appl WO 2003; 2003016270.
  • 34
    Soedervall M, Eloranta M, Kalapudas A. Method for the preparation of triphenylbutene derivatives. PCT Int Appl WO 2008; 2008/099059.
  • 35
    Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, Mcdonnell DP. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 1997; 138: 390111.
  • 36
    Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asano T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor β with low uterotrophic effect. Clin Cancer Res 2005; 11: 31522.
  • 37
    Shibutani S, Kim SY, Suzuki N. 32P-postlabeling DNA damage assays: PAGE, TLC and HPLC. In: Henderson DS, ed. DNA repair protocols: mammalian systems, 2nd edn. New Jersey, USA: Humana Press, 2005. 30721.
  • 38
    Toko T, Shibata J, Sugimoto Y, Yamada H, Yoshida M, Ogawa K, Matsushima E. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma. Cancer Chemother Pharmacol 1995; 37: 713.
  • 39
    Kim SY, Laxmi YRS, Suzuki N, Ogura K, Watabe T, Duffel MW, Shibutani S. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 2005; 33: 16738.
  • 40
    Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. I. Receptor interactions. J Med Chem 2003; 46: 883908.
  • 41
    Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. II. Clinical considerations and new agents. J Med Chem 2003; 46: 1081110.
  • 42
    Diez-Perez A. Selective estrogen receptor modulators (SERMS). Arq Bras Endocrinol Metabol 2006; 50: 72034.
  • 43
    Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007; 24: 36179.
  • 44
    Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008; 63: 16381.
  • 45
    Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002; 187: 5217.
  • 46
    Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007; 25: 496773.
  • 47
    Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 2000; 60: 6370.
  • 48
    Kang JS, Jung NJ, Kim S, Kim DJ, Jang DD, Yang KH. Downregulation of estrogen receptor α and β expression in carcinogen-induced mammary gland tumors of rats. Eksp Onkol 2004; 26: 315.
  • 49
    Okamoto Y, Liu X, Suzuki N, Okamoto K, Sekimoto M, Laxmi YRS, Shibutani S. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate. Int J Cancer 2008; 122: 21427.